92 results about "Vascular thrombosis" patented technology

The present invention relates to comprehensive systems, devices and methods for delivering energy to tissue for a wide variety of applications, including medical procedures (e.g., tissue ablation, resection, cautery, vascular thrombosis, treatment of cardiac arrhythmias and dysrhythmias, electrosurgery, tissue harvest, etc.). In certain embodiments, systems, devices, and methods are provided for treating a tissue region (e.g., a tumor) through application of energy.

The present invention relates to systems and devices for delivering energy to tissue for a wide variety of applications, including medical procedures (e.g., tissue ablation, resection, cautery, vascular thrombosis, treatment of cardiac arrhythmias and dysrhythmias, electrosurgery, tissue harvest, etc.). In particular, the present invention relates to systems and devices for the delivery of energy with heat transfer ability. In some embodiments, the systems and devices also have variable characteristic impedance as a result of the use of heat transfer materials. In certain embodiments, methods are provided for treating a tissue region (e.g., a tumor) through application of energy with the systems and devices of the present invention.

The present invention relates to systems and devices for delivering energy to tissue for a wide variety of applications, including medical procedures (e.g., tissue ablation, resection, cautery, vascular thrombosis, treatment of cardiac arrhythmias and dysrhythmias, electrosurgery, tissue harvest, etc.). In particular, the present invention relates to systems and devices for the delivery of energy employing a center fed dipole component. In certain embodiments, methods are provided for treating a tissue region (e.g., a tumor) through application of energy with the systems and devices of the present invention.

The present invention relates to systems and devices for delivering energy to tissue for a wide variety of applications, including medical procedures (e.g., tissue ablation, resection, cautery, vascular thrombosis, treatment of cardiac arrhythmias and dysrhythmias, electrosurgery, tissue harvest, etc.). In particular, the present invention relates to systems and devices for the delivery of energy with optimized characteristic impedance. In certain embodiments, methods are provided for treating a tissue region (e.g., a tumor) through application of energy with the systems and devices of the present invention.

The present invention relates to comprehensive systems, devices and methods for delivering energy to tissue for a wide variety of applications, including medical procedures (e.g., tissue ablation, resection, cautery, vascular thrombosis, treatment of cardiac arrhythmias and dysrhythmias, electrosurgery, tissue harvest, etc.). In certain embodiments, systems, devices, and methods are provided for delivering energy to difficult to access tissue regions (e.g. peripheral lung tissues), and/or reducing the amount of undesired heat given off during energy delivery.

The present invention relates to systems and devices for delivering energy to tissue for a wide variety of applications, including medical procedures (e.g., tissue ablation, resection, cautery, vascular thrombosis, treatment of cardiac arrhythmias and dysrhythmias, electrosurgery, tissue harvest, etc.). In particular, the present invention relates to systems and devices for the delivery of energy with a linear array of antenna components having optimized energy delivery characteristics. In certain embodiments, methods are provided for treating a tissue region (e.g., a tumor) through application of energy with the systems and devices of the present invention.

The present invention relates to comprehensive systems, devices and methods for delivering energy to tissue for a wide variety of applications, including medical procedures (e.g., tissue ablation, resection, cautery, vascular thrombosis, treatment of cardiac arrhythmias and dysrhythmias, electrosurgery, tissue harvest, etc.). In certain embodiments, systems, devices, and methods are provided for treating a tissue region (e.g., a tumor) through application of energy.

This invention is directed to methods of preventing or treating diseases or conditions associated with excessive cell proliferation, remodeling, inflammation, and vasoconstriction. Particularly, this invention is directed to methods of treating cardiovascular diseases or conditions such as stent restenosis and thrombosis, vascular thrombosis, cerebral vasospasm, atherosclerosis, systemic hypertension, cardiac hypertrophy, and sexual dysfunction. The method comprises identifying a subject in need of the treatment, and administering to the subject an effective amount of a novel Rho kinase inhibitor compound to treat the disease.

The present invention relates to comprehensive systems, devices and methods for delivering energy to tissue for a wide variety of applications, including medical procedures (e.g., tissue ablation, resection, cautery, vascular thrombosis, treatment of cardiac arrhythmias and dysrhythmias, electrosurgery, tissue harvest, etc.). In certain embodiments, systems, devices, and methods are provided for treating a tissue region (e.g., a tumor) through application of energy.

The present invention is directed to a system and method for postoperative monitoring of the condition of a tissue or organ utilizing sensors that may be embedded in various types of surgical drains. The system is comprised of a probe and a monitoring unit. The probe may include a surgical drain with fluid draining channels housing one or more sensors to measure various parameters of the adjacent tissue. The monitoring unit which controls the sensors of the probe may include a processor to process, record and display the measured parameters. This system may be valuable for monitoring transplanted organs and tissue grafts during the critical postoperative period when most of the clinical complications, such as vascular thrombosis, may occur.

Provided herein are devices, systems, and methods for delivering energy to tissue for a wide variety of applications, including medical procedures (e.g., tissue ablation, resection, cautery, vascular thrombosis, treatment of cardiac arrhythmias and dysrhythmias, electrosurgery, tissue harvest, etc.). In certain embodiments, devices, systems, and methods are provided for delivering energy to difficult to access tissue regions (e.g. central or peripheral lung tissues), and/or reducing the amount of undesired heat given off during energy delivery.

The present invention is directed to a system and method for monitoring the physiological parameters of an organ or tissue during and after surgery. The system has a probe and a monitoring unit. In one embodiment the probe includes features for convenient, fixed and releasable attachment to surgical drains without interfering with their normal fluid-draining function while utilizing their suction to enhance the probe-to-tissue interface for improved sensing. An applicator is provided to facilitate such attachment. The monitoring unit which controls the sensors of the probe includes a processor to process, record and display the sensor data. This system may be valuable for monitoring transplanted organs and tissue grafts during the critical postoperative period when most of the clinical complications, such as vascular thrombosis, may occur.

The invention discloses a tanshinone IIA-polyactic acid/hydroxyacetic acid microsphere and a preparation method thereof. The microsphere is prepared by drying oil-in-water type emulsion, wherein the oil phase is dichloromethane solution of a polyactic acid/hydroxyacetic acid copolymer and the water phase is the water solution of polyvinyl alcohol. The drug content of tanshinone IIA in the microsphere is 1-10% and the entrapment efficiency is 60-90%. The particle size range of the microsphere is 30-200mm. The tanshinone IIA-polyactic acid/hydroxyacetic acid microsphere provided by the invention is suitable for interventional therapy of liver cancers, has a good liver tumor peripheral vascular thrombosis function, has an effective thrombosis time of 7-60 days, can be distributed in tumor tissues in a targeted manner, slowly release drugs, increase the local concentrations of the drugs, prolong the drug metabolism time, obviously inhibit animal liver tumor growth and prolong the animal lifetime and can inhibit expressions of a human hypoxia inducible factor 1alpha and a vascular endothelial growth factor and reduce the tumor tissue microvessel density after thrombosis.

The invention discloses a preparation method of a polysaccharide-polyvinyl alcohol embolism microsphere, wherein the polysaccharide-polyvinyl alcohol embolism microsphere is an elastic microsphere which is formed by blending and cross-linking polyvinyl alcohol and polysaccharide natural polymers. The preparation method comprises the following steps: blending polyvinyl alcohol and polysaccharide natural polymers so as to form polysaccharide-polyvinyl alcohol mixed liquids different in proportion; and partially cross-linking the mixed liquids, and emulsifying with uncross-linked part so as to obtain a cross-linked vascular thrombosis microsphere, namely the polysaccharide-polyvinyl alcohol embolism microsphere. The polysaccharide-polyvinyl alcohol embolism microsphere is relatively high in flexibility and elasticity and is convenient for delivering micro catheters, and the preparation method is simple; meanwhile, embolism cycle can be controlled in accordance with the situations of various tumor symptoms, so as to effectively avoid the circumstance of multiple embolisms; and the preparation method is convenient for clinical application.

The invention discloses a face filling agent composition for injection type cosmetic plastic surgery and a preparation method of the face filling agent composition, relates to a ace filling agent composition for cosmetic plastic surgery and a preparation method of the face filling agent composition, and aims to solve the problems that conventional cross-linked hyaluronic acid is poor in cross-linking effect, a user has red and swelling inflammation, potential safety hazards can be caused, not only is a skin repairing effect not achieved, but also vascular thrombosis can be possibly caused. Theface filling agent composition for injection type cosmetic plastic surgery comprises a cross-linked hyaluronic acid composite gel, hydroxyapatite micro particles, collagen powder, cellulose ethers, an epimedium herb extract, a white peony root extract and an injection aqueous solution. The method comprises the following steps: I, weighing materials; and II, performing mixing and sterilization. The face filling agent composition for injection type cosmetic plastic surgery, which is prepared by the invention, has a use mode of being injected into dermis of a part to be filled, of a face. The invention obtains the face filling agent composition for injection type cosmetic plastic surgery.

The herein invention refers to a purifying process of soluble proteins of the L. obliqua bristles through prothrombin activation; a partial deterrination of the amino acids sequence of the prothrombin activator; a process for determining the fraction II of the prothrombin activation as well as the N-terminal sequence and the sequence of internal fragments of the prothrombin activator fraction, the prothrombin activator and the utilization of the prothrombin activator through the homogenization of the L. obliqua bristles. The herein invention has shown that only one component of the Lonomia obliqua venom, the Lopap, causes the hemorrhagic syndrome directly by activating prothrombin and, therefore, a patient should be conducted to a therapy when in contact with the Lonomia obliqua venom. According to the herein invention, Lopap is a new prothrombin activator, showino to be a quite important factor responsible for consumption coagulopathy, found in patients exposed to the venom of the L. obliqua caterpillar. In low doses of purified protein, due to its capacity of activating prothrombin and generating thrombin, it is possible, in controlled conditions, to withdraw fibrinogen from circulation, transforming it in fibrin microthrombs. The decrease on the concentration of plasmatic fibrinogen promotes the increasing of blood coagulation time and therefore it will avoid acute vascular thrombosis. Since protein does not present proteolytic activity, it could maintain the coagulating capacity of the fibrinogen not consumed in the process. The fibrinogen plasmatic concentration would decrease, however there would not be predisposition for hemorrhagic state. Besides that, it could be used to produce diagnosis KITS for detecting dysprothrombinemias.

The present invention relates to comprehensive systems, devices and methods for delivering energy to tissue for a wide variety of applications, including medical procedures (e.g., tissue ablation, resection, cautery, vascular thrombosis, treatment of cardiac arrhythmias and dysrhythmias, electrosurgery, tissue harvest, etc.). In particular, systems, devices, and methods are provided for treating a tissue region (e.g., a tumor) through application of energy using energy delivery devices with flexible and adjustable tips.

The invention discloses a polyvinyl alcohol nanofiber emboliaztion agent as well as a preparation method and application thereof and belongs to the field of vascular thrombosis materials for interventional therapy. The polyvinyl alcohol nanofiber emboliaztion agent consists of polyvinyl alcohol electrostatic spinning nanofiber granules, wherein the particle sizes of the nanofiber granules is 100-300mu m. The preparation method comprises the following steps: dissolving polyvinyl alcohol granules into water, and heating till the polyvinyl alcohol granules are completely dissolved so as to obtaina polyvinyl alcohol solution of an appropriate concentration as an electrostatic spinning solution; preparing a polyvinyl alcohol nanofiber film from the electrostatic spinning solution by using electrostatic spinning equipment; performing thermal treatment on the nanofiber film; shearing the nanofiber film after thermal treatment, performing low-temperature crushing treatment, and screening, thereby obtaining the polyvinyl alcohol nanofiber granules of which the particle size is 100-300mu m. The emboliaztion agent disclosed by the invention has relatively good treatment effects and biological security, and can be also applied to arterial embolism of various types of malignant tumor such as primary liver cancer and kidney cancer.

The invention relates to a device for dredging cardio-cerebral vessels and cleaning vascular thrombosis, and belongs to the technical field of medical appliance structures. The device comprises a guiding catheter, wherein an inflatable balloon which can be inflated and deflated is arranged on the outer wall of the guiding catheter, and a microcatheter is inserted in the guiding catheter; a part of the microcatheter is positioned inside the guiding catheter, and a part of the microcatheter is positioned outside the guiding catheter; a driving mechanism used for driving the microcatheter to rotate and a sucking device are arranged on the microcatheter; sucking holes are distributed in partial wall of the microcatheter; a micro-guiding wire is inserted in the microcatheter; a detachable anti-thrombus ball net is arranged at one end of the micro-guiding wire; and a reticular vessel stent for supporting vessels is arranged outside the micro-catheter, and is of a cylindrical shape after being unfolded. The device is reasonable in structure design, simple and convenient to operate and strong in plasticity, can be used for sucking and cleaning thrombus while dredging vessels, and has a vessel supporting effect.

A stent for coronary vessels, having a surface of multilayer immobilized structures, includes a stent body and a number of polyelectrolyte complex (PEC) layers stacking and being immobilized on the surface of the stent body, in which the PEC layer is formed of a polymer layer and an anticoagulant layer. The coronary stent is capable of effectively improving the hemocompatibility longevity over conventional stent using surface encapsulation of an anticoagulant layer for hemocompatibility improvement. Furthermore, the coronary stent can be use as a drug-eluting coronary stent, thus allowing for the time-releasing of drugs, and further preventing the thickening of vascular smooth muscle cells for causing vascular thrombosis.

The invention discloses a yoghourt beverage containing bacillus coagulans, and a making method of the yoghourt beverage containing bacillus coagulans, and belongs to the technical field of food processing. The yoghourt beverage consists of the following components in parts by weight: 10-12 parts of bacillus coagulans liquid, 80-90 parts of soybeans, 20-30 parts of peanut kernels, 6-8 parts of human plasminogen protein, 120-150 parts of embedding carriers, 11-15 parts of complex enzymes, 25-35 parts of externally-applied substances, 200-400 parts of skimmed milk, 50-60 parts of whey protein powder, 5-10 parts of a stabilizing agent, 10-17 parts of a thickening agent, 40-50 parts of sweet substances, 25-30 parts of a flavor adjusting agent, 18-25 parts of nutrient enrichment substances and 100-150 parts of purified water. According to the yoghourt beverage and the making method thereof disclosed by the invention, bacillus coagulans is used for replacing conventional probiotics for fermentation, and is resistant to acid, resistant to heat, resistant to salt, easy to culture and easy to preserve; and the added human plasminogen protein can regulate blood vessel proliferation and can effectively prevent vascular thrombosis. In short, the yoghourt made by the making method disclosed by the invention is good in texture, good in mouth feel, rich in nutrition and easy to absorb.